Figure S9 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
Year: 2023
Type: other
Abstract: Canine primary lung cancer cell line sensitivity to trastuzumab. Five canine cell lines (three HER2WT and two HER2V659E) and one human cell line BT474 (HER2amp) were treated with 10 trastuzumab doses ranging from 1x10-6 μg/ml to 1000 μg/ml for 72 hours with CellTiterGlo viability endpoints measured and shown as percent growth inhibition relative to PBS vehicle control. Relative survival was measured with respect of the sensitive cell line BT474.
Authors: Gwendolen Lorch, Karthigayini Sivaprakasam, Victoria Zismann, Nieves Perdigones, Tania Contente-Cuomo, Alexandra Nazareno, Salvatore Facista, Shukmei Wong, Kevin Drenner, Winnie S. Liang, Joseph M. Amann, Sara L. Sinicropi-Yao, Michael J. Koenig, Krista La Perle, Timothy G. Whitsett, Muhammed Murtaza, Jeffrey M. Trent, David P. Carbone, William P.D. Hendricks
Language: English
Topic: Veterinary Oncology Research
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362408895